Safety, pharmacokinetics, and antiviral activity of the capsid inhibitor AB‐506 from Phase 1 studies in healthy subjects and those with hepatitis B

AB‐506 is a potent, pan‐genotypic small molecule capsid inhibitor that inhibits hepatitis B virus (HBV) pregenomic RNA encapsidation. We assessed the safety, pharmacokinetics, and antiviral activity of AB‐506 in two randomized, double‐blinded Phase 1 studies in healthy subjects (HS) and subjects wit...

Descripción completa

Detalles Bibliográficos
Autores principales: Yuen, Man‐Fung, Berliba, Elina, Sukeepaisarnjaroen, Wattana, Ahn, Sang Hoon, Tanwandee, Tawesak, Lim, Young‐Suk, Kim, Yoon Jun, Poovorawan, Kittiyod, Tangkijvanich, Pisit, Schwabe, Christian, Eley, Timothy, Brown, Joanne, Lee, Amy C. H., Thi, Emily P., Paratala, Bhavna, Mani, Nagraj, Sofia, Michael J., Picchio, Gaston, Sims, Karen D., Gane, Edward J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9701477/
https://www.ncbi.nlm.nih.gov/pubmed/36194181
http://dx.doi.org/10.1002/hep4.2095

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9701477/
https://www.ncbi.nlm.nih.gov/pubmed/36194181
http://dx.doi.org/10.1002/hep4.2095

Ejemplares similares